A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

Files in this item

This item appears in the following Collection(s)

Available in accordance with the Publisher Policy. Please refer to the publisher's site for terms of use.

Search Repository

My Account